Article
Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.
Gastroenterology - 1 Nov 2012
Lenz Oliver, de Bruijne Joep, Vijgen Leen, Verbinnen Thierry, Weegink Christine, Van Marck Herwig, Vandenbroucke Ina, Peeters Monika, Simmen Kenneth, Fanning Greg, Verloes Rene, Picchio Gaston, Reesink Hendrik
Abstract excerpt
In the TMC435-C101 study, 6 patients infected with hepatitis C virus genotype 1 were treated with the protease inhibitor TMC435 (200 mg once daily) as monotherapy for 5 days. Approximately 1.5 years later, 5 of these patients were re-treated with TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week 48 (in the Optimal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.